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Abstract
A rapid, low cost, accurate point-of-care (POC) device to detect influenza virus is needed for effective treatment and control
of both seasonal and pandemic strains. We developed a single-use microfluidic chip that integrates solid phase extraction
(SPE) and molecular amplification via a reverse transcription polymerase chain reaction (RT-PCR) to amplify influenza virus
type A RNA. We demonstrated the ability of the chip to amplify influenza A RNA in human nasopharyngeal aspirate (NPA)
and nasopharyngeal swab (NPS) specimens collected at two clinical sites from 2008–2010. The microfluidic test was
dramatically more sensitive than two currently used rapid immunoassays and had high specificity that was essentially
equivalent to the rapid assays and direct fluorescent antigen (DFA) testing. We report 96% (CI 89%,99%) sensitivity and
100% (CI 95%,100%) specificity compared to conventional (bench top) RT-PCR based on the testing of n=146 specimens
(positive predictive value=100%(CI 94%,100%) and negative predictive value=96%(CI 88%,98%)). These results compare
well with DFA performed on samples taken during the same time period (98% (CI 91%,100%) sensitivity and 96%(CI
86%,99%) specificity compared to our gold standard testing). Rapid immunoassay tests on samples taken during the
enrollment period were less reliable (49%(CI 38%,61%) sensitivity and 98%(CI 98%,100%) specificity). The microfluidic test
extracted and amplified influenza A RNA directly from clinical specimens with viral loads down to 10
3 copies/ml in 3 h or
less. The new test represents a major improvement over viral culture in terms of turn around time, over rapid immunoassay
tests in terms of sensitivity, and over bench top RT-PCR and DFA in terms of ease of use and portability.
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Introduction
In a normal year, the influenza virus infects millions of
individuals [1] causing approximately 350,000 hospitalizations
and 50,000 deaths in the United States [2,3]. Furthermore, when
genetic rearrangements result in antigenic shift in the virus, a
pandemic strain can result [4]. In April 2009, worldwide
surveillance efforts identified the emergence and rapid spread of
a novel influenza A strain, which reached pandemic levels as
defined by the World Health Organization (WHO) in early June
of 2009 [5]. As of August 2010, worldwide more than 214
countries and overseas territories or communities had reported
laboratory confirmed cases of pandemic influenza H1N1 2009,
including 18,449 deaths [6].
The most recent pandemic highlighted weaknesses in the
methods widely used to diagnose influenza: rapid immunoassays
(antigen tests), direct fluorescent antigen testing (DFA), and viral
culture methods (culture followed by immunofluorescence or
hemagglutination assay for virus identification) [7]. During the
pandemic, rapid influenza tests on the market were widely used
and found to be dramatically lacking in sensitivity [8,9,10,11] such
that the Centers for Disease Control and Prevention (CDC,
Atlanta, GA) recommended that a negative test result be ignored
for clinical decision-making [12]. Although the DFA test worked
well during the 2009 H1N1 pandemic [13,14], the labor-intensive
nature of the test and potentially subjective aspects of results
interpretation somewhat reduced its utility [7]. While now being
debated, viral culture remains the ‘‘gold standard’’ test; however, it
requires 2–7 days to complete and lacks the ability to distinguish
between different respiratory viruses and between influenza virus
types without follow up testing [7]. Alternatively, polymerase chain
reaction (PCR) testing provides a faster turnaround time, high
sensitivity and high specificity. The vast amount of PCR data
generated during the 2009 H1N1 pandemic supported the
hypothesis that PCR performs as well or better than culture,
including the ability to verify and differentiate influenza types and
subtypes [8,9,15].
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have been United States Food and Drug Administration (FDA)
approved, including the Xpert
TM Flu A panel (Cepheid,
Sunnyvale, CA), the Iquum Liat
TM Influenza A/2009 H1N1 test
(Iquum, Marlborough, MA), the Luminex xTAGH Respiratory
Viral Panel (Luminex, Austin, TX) and the Prodesse ProFAST
TM
assay (Gen-Probe, San Diego, CA). The Luminex and Gen-Probe
tests require off-chip sample preparation either by hand or using a
separate automated sample preparation system, requiring either a
bench top kit and centrifuge or additional instruments and
reagents. The Cepheid and Iquum tests do include sample
preparation in the cartridge, but the tests are not Clinical
Laboratory Improvement Amendments (CLIA) waived or point-
of-care (POC). Clinical utility would be greatly enhanced by a
CLIA waived molecular test that could be performed at the
bedside, since a CLIA waiver allows testing and analysis of results
to take place outside of the clinical laboratory by trained
personnel. Here we demonstrate a proof-of-concept microfluidic
chip using clinical specimens collected over a two-year period from
patients with suspected influenza. The microfluidic assay uses a
nucleic acid extraction method and a PCR thermal cycling
strategy chosen for their relative ease and simplicity.
Since the introduction of the concept of the micro total analysis
system (m-TAS) in 1990 [16] and the introduction of the first PCR
chip in 1993 [17], miniaturization of PCR devices has been
extensively studied [18,19]. Improvements have included faster
amplification [20,21], reduced sample and reagent consumption
[22,23], single-use chip materials [24] and increased integration of
the PCR device with sample preparation and detection modules
[25,26,27,28,29]. Only a few reports have demonstrated integrat-
ed chips with molecular diagnostic capabilities using complex
clinical specimens [30,31,32]. Others have demonstrated on chip
RT-PCR with simulated human specimens [33,34,35]. Here we
focus on clinical specimens collected during the 2008–2010
influenza seasons. Clinical specimens present many difficulties
including inhomogeneity, variations in viral load, different levels of
contaminating human cells and blood, the presence of PCR
inhibitors after nucleic acid extraction [36,37] and unanticipated
chemical and/or physical reactions between the specimens and the
test reagents or the device itself [38]. The single-use chip proposed
here incorporates nucleic acid extraction and reverse transcrip-
tion-PCR (RT-PCR) in a single chip with simple thermal and
fluidic control. The single use feature decreases the possibility of
cross contamination between specimens, and the small form factor
makes it a good candidate for true POC testing.
Results
Overview of Experimental Design
A total of 626 specimens were collected from two sites during
2008–2009 and 2009–2010 influenza seasons. All of the samples
were characterized in our laboratory using bench top RT-PCR,
which we define here as the reference method. In order to
determine the analytical limit of detection for the single use
influenza A assay, the microfluidic assay was first tested using a
laboratory strain of influenza A (VR-1469, H1N1, A/PR/8/34
obtained from ATCC, Manassas, VA). The limit of detection
determined using this laboratory strain was 10
5 copies per milliliter
of input sample (Figure S1). Before working with the human
samples, the assay was optimized for bovine serum albumin (BSA),
magnesium ion, and enzyme concentrations in order to push the
limit to 10
4 cp/ml (Figures S2, S3, S4). Next, nasopharyngeal
aspirate (NPA) and nasopharyngeal swab (NPS) specimens that
were collected with Institutional Review Board approval from
patients presenting with symptoms consistent with influenza to two
Boston hospitals, as described in the methods, were tested by
bench top RT-PCR. A total of 146 samples were then selected (73
positive and 73 negative by bench top RT-PCR) from this pool,
without regard to viral load, for testing with the microfluidic assay.
Results of DFA (n=106) and rapid immunoassay (n=119) testing
that had been performed on specimens as part of routine care at
each of the two hospitals were also compared to results obtained
from testing of those specimens by our bench top PCR reference
standard. While there was some overlap in the sample sets, in
general, different samples were used to compare each method
(microfluidic, DFA, and rapid immunoassay) to bench top RT-
PCR. Reagents described in the CDC research-use only (RUO)
protocol for real-time PCR of influenza A and B were used in the
gold-standard bench top PCR assay [39].
Microfluidic assay: human specimens
A set of human nasopharyngeal swab (n=35) and aspirate
(n=111) samples were tested in the single use microfluidic assay
(n=146). All of the samples (n=146) were also tested for both
influenza A and influenza B in our laboratory using bench top
quantitative RT-PCR. Quantification of the microfluidic assay
output is summarized in Table S1. The specimens tested in the
microfluidic assay included n=73 specimens positive for influenza
A and n=73 specimens negative for influenza A by bench top
RT-PCR. The 73 influenza A negative specimens included 20
samples that tested negative for influenza A but positive for
influenza B by the bench top reference assay in our laboratory.
The disposable microfluidic assay included sample injection after
mixing with lysis buffer (see Methods), nucleic acid isolation by solid
phase extraction (SPE) (nucleic acid extraction), reverse transcrip-
tion (RT) and continuous flow polymerase chain reaction (PCR)
(Figure 1). Products were detected off-chip by capillary electro-
phoresis. Each test was completed in 3 hours or less. The test time
included approximately 110 min for sample preparation, 30 min
for RT, 15 min for polymerase activation, 20 min for PCR, and
5 min for off-chip detection. It took more than 4 hours to complete
the same steps for the gold standard RT-PCR assays. The sample
preparation is the rate-limiting step in the current chip design.
Simple modifications to greatly reduce the time spent on this step
are covered in the discussion. The bench top assays also required
many more handling steps. The PCR products were verified by gel
electrophoresis (2100 Bioanalyzer and 12% PAGE) and a subset of
the positive results were verified by sequencing. The on-chip PCR
product yield ranged from 43 pg/ml to 1.5 ng/ml. The majority
(77%) of the amplicons had endpoint concentrations between 0.1–
1.0 ng/ml. Periodically, products from the positive reactions
(specifically, every 10
th product) were sequenced for quality control.
The sequences were submitted to the GenBank database (accession
numbers HM370561-HM370565; HQ902243-HQ902250). A
BLAST search of the sequenced region returned results of 98–
100% homology for all sequences (n=13) with the influenza A M1
gene in segment 7 from GenBank. Next, all of the chip product
sequences were aligned with the standard reference influenza strain
A/PR/8/34M1gene (positionnumber171to276inM1,accession
number NC_002016).
All sequences were confirmed to be from influenza A; 12/13 of
the specimens sequenced had greater than 98.2% homology with
the reference, and one was 94.7% homologous. We observed
variance of the sequence at position 199 in 9/13 sequences between
guanine and adenine, and further sequence changes were observed
in specimen ID 63 (Figure 2). To determine if these positions were
variable in M1 and to determine the frequency of variations at these
positions, we retrieved all (n=739) GenBank M1 sequences isolated
Disposable Molecular Diagnostic for Influenza A
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in North America from the NCBI’s Influenza Virus Resource
database [40]. The sequences were aligned using the Influenza
Virus Resource alignment tool. Adenine was found to be a common
base at position 199, occurring in 66% of the sequences. Three
positions in specimen ID 63 were altered; the same 2/3 variations
were observed at low frequency in the database (0.3%–0.7%)),
however we did not find the third variation, an insertion, in the
database. All positive reactions and every 10
th negative reaction (a
subset is shown in Figure3) wereverified by 12% PAGE, with RT-
PCR positive products at 106 bp and negative specimens showing
only primer dimers as expected.
The microfluidic assay for influenza A did not generate any false
positives, including for those specimens shown to be RT-PCR
Figure 1. The microfluidic assay flow. (A) Image of two microfluidic chips with attached thin film heaters and the two-barrel syringe pump. Glass
syringes were connected to each chip with flexible tubing to load reagents and samples. Three ports were glued at the inlets of SPE channel and the
waste port, and the outlet of the PCR channel. (B) Channel design with three sections: sample preparation (SPE), RT chamber and continuous flow
PCR channel. Two fixed resistance heaters are attached via thermal tape to the bottom of the chip. Fluid flow between the channels was linear, and
changes in fluid resistance allowed for valveless operation. The depth is 500 mm for SPE and RT channels, and the PCR channel is 100 mm deep. The
widths are 500 mm for the SPE column, 1 mm for the RT chamber, and vary from 200 to 400 mm for the wide and narrow sections of the continuous
flow PCR channel. The chip is 70 mm in length, 25 mm in width and 1.4 mm in height. (C) Microfluidic assay process flow. The nasopharyngeal
sample is mixed with lysis buffer, applied to the chip, the chip is run, and the PCR products are read using a commercial capillary electrophoresis chip.
doi:10.1371/journal.pone.0033176.g001
Figure 2. Sequence alignment of microfluidic assay RT-PCR products to standard reference influenza strain A/PR/8/34 M1 gene
(position number: 193–252). The sequence presented here excludes primer sequences.
doi:10.1371/journal.pone.0033176.g002
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specificity of 100%. For specimens with greater than 10
5 copies/
ml viral loads, the sensitivity was 100%. Viral load was determined
using absolute quantification by real time PCR (methods). The
sensitivity decreased to 96% when specimens with viral loads
down to 10
3 copies/ml were included (Table 1). None of the
specimens assayed had measured viral loads of less than 10
3
copies/ml. Based on all specimens tested in the microfluidic assay
(n=146), the sensitivity and specificity were 96%(CI 89%,99%)
and 100%(CI 95%,100%), respectively (Table 2).
As expected, there is significantly higher PCR product yield
with increased RNA template input from higher viral loads (one-
way ANOVA, p,0.001) (Figure 4). Two different specimen types
(NPA and NPS) were tested in the microfluidic assay. Similar
trends were found for both specimen types, with no observable
difference between swab and aspirate samples (Figure 4).
Other methods
To compare the performance of techniques in clinical use to the
bench top RT-PCR performed in our laboratory, we selected
additional specimens from our sample library that had been
previously tested as part of routine clinical care using rapid
immunoassays (Boston Medical Center) or DFA (Beth Israel
Deaconess Medical Center). In total, n=106 samples tested by
Figure 3. Representative on-chip RT-PCR products on 12% polyacrylamide gel. P: cultured influenza A virus (A/PR/8/34) microfluidic assay
result. N: negative control (nuclease free water) in microfluidic chip result. Positive specimens: 26B, 53, 27B, 20B, 22B, 21B, 115, 117, 31B, 30B, 171.
negative specimens: 149, 56, 24, 92, 45, 173, 302, 64, 272, 22, 24, 112, 150, 307, 173, 118, 91, 20, 32, 6, 8. L: GeneRuler
TM Ultra Low Range DNA Ladder
(Fermentas, Glen Burnie, Maryland).
doi:10.1371/journal.pone.0033176.g003
Table 1. Cumulative sensitivity and specificity of the microfluidic assay for influenza A for decreasing specimen viral loads.
No. of specimens (n) in
each viral load ‘‘bin’’
False negatives
in each ‘‘bin’’
Cumulative no.
of specimens
Cumulative number
of false negatives Sensitivity Specificity
Viral load
(copies/ml)
1 0 1 0 100% 100% 10
10
11 0 12 0 100% 100% 10
9
29 0 41 0 100% 100% 10
8
17 0 58 0 100% 100% 10
7
8 0 66 0 100% 100% 10
6
3 2 71 2 97% 100% 10
5
2 1 74 3 96% 100% 10
4
2 0 76 3 96% 100% 10
3
doi:10.1371/journal.pone.0033176.t001
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included in the testing and analysis. These sample sets are
summarized in Tables S2 and S3. The DFA tests were 98%(CI
91%,100%) sensitive and 94%(CI 86%,99%) specific when
compared to RT PCR run in our laboratory, with 1 false negative
(NPV=98%) and 2 potential false positives (PPV=97%). The
rapid immunoassays (Xpect Flu
TM and BinaxNOW
TM) were
49%(CI 38%,961%) sensitive and 98%(CI 90%,100%) specific
(n=119), with 1 false positive (PPV=97%) and 34 false negatives
(NPV=60%) (Tables 3 and 4).
Discussion
Rapid, sensitive, and cost-effective detection of influenza virus
from clinical specimens is critical for effective treatment and to
limit the spread of infection. In this study, we miniaturized a
nucleic acid amplification test into a single-use microfluidic chip to
reduce the testing cost, decrease the turnaround time and move
the PCR assay closer to true POC testing. We assessed the ability
of the microfluidic chip to amplify influenza A virus RNA in
clinical nasopharyngeal specimens.
146 specimens were chosen from the sample pool to test the
microfluidic assay. Independently, two subsets of specimens that
had been routinely tested using either a DFA (n=106) or rapid
immunoassay (n=119) test as the standard of care were tested
with the reference bench top RT-PCR assay. Compared to bench
top RT-PCR as the gold standard, the microfluidic test performed
with sensitivity and specificity comparable to the DFA assays that
had been performed as standard of care, and with substantially
greater clinical sensitivity (96% vs. 49%) than the rapid
immunoassays that had been performed as standard of care.
The 73 clinical specimens negative for influenza A by both bench
top and microfluidic assays included 20 samples that were positive
for influenza B by the bench top gold standard assay. Specimens
with initial viral loads down to 10
3 copies/ml were detected as
positive in the microfluidic assay, although with reduced sensitivity
Table 2. Summary statistics for the microfluidic assay.
Microfluidic Assay vs. Benchtop RT-PCR
(n=146) positive negative
Positive 70 0 100% (94%,100%) PPV
Negative 37 3 96% (88%,98%) NPV
96% (89%,99%) 100% (95%,100%)
Sensitivity Specificity
(95% CI).
doi:10.1371/journal.pone.0033176.t002
Figure 4. On-chip PCR product concentration vs. copy number showing NP swab and NP aspirate specimens.
doi:10.1371/journal.pone.0033176.g004
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A copy numbers of greater than or equal to 10
5 copies/ml and was
96% for specimens with copy numbers greater than or equal to
10
3 copies/ml. Typical viral loads in the nasopharynx for patients
recently infected with influenza A are rarely below 10
4 copies/ml
[41,42], and this has been verified for several strains [43]. So,
while there are several ways that the reported microfluidic assay
could be improved to lower the limit of detection, in the case of
influenza A infections, this improvement would be of limited
benefit.
It is important to note that the low sensitivity of the rapid
immunoassays was expected. Because in previous work by Pollock
et al. [14], the DFA assay results were comparable to the
performance of bench top RT-PCR, we closely examined our
potential DFA false positive (2) and false negative (1) results. In the
two DFA positive/bench top RT-PCR negative specimens, the
patients who provided the specimens were clinically diagnosed
with influenza based on compatible symptoms and signs, and each
specimen was collected during the pH1N1 epidemic in Boston.
One limitation of the bench top RT-PCR used in this study was
that the assays were performed on the clinical specimens after they
had undergone at least one freeze/thaw cycle, which may have led
to some RNA degradation in the sample and thus slightly reduced
the sensitivity of the gold standard RT-PCR. We hypothesize that
this could potentially explain the two DFA-positive, bench top
PCR-negative results. The DFA negative/bench top RT-PCR
positive specimen was one which was already known to have low
numbers of epithelial cells and was accordingly borderline
inadequate for DFA testing [14]; a separate specimen from the
same patient had tested positive for pH1N1 by RT-PCR testing
done at the Massachusetts State Laboratory, confirming our own
bench top RT-PCR results.
We plotted the input viral load as determined by the bench top
quantitative PCR against the amplicon output concentration from
the microfluidic assay measured using capillary electrophoresis
(Figure 4). Since these were endpoint reads, we did not expect a
strong linear relationship between input copy number and
endpoint concentration (linear regression R
2=0.174 for NPA
specimens and R
2=0.253 for NPS specimens), and we did not see
one.
All of the microfluidic assays were run with the same primer,
enzyme and blocking agent starting concentrations. These
concentrations were chosen based on a series of preliminary
optimization experiments that are described in the data (Figures
S1, S2, S3, S4). The only variable in the reaction was the input
sample, which varied in several ways. First, there was variation in
the viral load between specimens. There were also differences in
sample type (NPA vs. NPS) and in the method of storage before
microfluidic testing. The samples collected at BMC were
aliquotted and stored in VTM, while almost all of the samples
collected at BIDMC were not aliquotted and were stored in PBS (a
minority of specimens were stored in VTM). The aliquotting
allowed for minimal freeze thaws before testing the samples in the
reference bench top RT-PCR assay and the microfluidic chip
assay. Most of the samples went through one freeze/thaw cycle
before microfluidic testing and the bench top RT-PCR. In
addition, all samples were spun once before introduction into the
microfluidic chip. The BMC samples were spun before aliquots
were frozen, and the BIDMC samples were spun after aliquots
were thawed fore testing in the microfluidic assay. This
‘‘preprocessing’’ step was performed to minimize the chance of
clogging the nucleic acid extraction part of the chip with cell
debris, which was seen in a small number (about 10%) of the
preliminary experiments due to the very small pore size of the SPE
columns used in these chips. Recent reformulations of the SPE in
our lab have resulted in larger average pore sizes that have
eliminated the need for this initial spin down step. It is possible,
however that the spin step also acted to remove PCR inhibitors,
resulting in better results than had the samples been left
completely untreated.
The PCR channel design used in the microfluidic assay was
optimized previously to achieve repeatable and predictable
temperature profiles in the chip [44]. The serpentine PCR
channel flows the sample through 30 cycles of PCR. The cycle
number is fixed for any given chip, unlike in bench top PCR
schemes. Increasing the cycle number (by redesigning the chip)
and/or reducing the flow rate could further improve the PCR
yield, but testing time would also increase. So, for any given assay,
the chip design and the PCR reaction itself must be optimized
simultaneously. Here, a validated protocol obtained from the
CDC was adapted for use in the microfluidic chip. Only the
influenza A primer set from the CDC protocol was used in the
microfluidic assay. In place of the other reagents, we used reagents
Table 3. Summary statistics for DFA.
DFA
vs. Benchtop RT-
PCR
(n=106) positive negative
Positive 58 2 97% (89%,99%) PPV
negative 14 5 98% (89%,100%) NPV
98% (91%,100%) 96% (86%,99%)
Sensitivity Specificity
(95% CI).
doi:10.1371/journal.pone.0033176.t003
Table 4. Summary statistics for the rapid immunnoassays.
Rapid Immunoassays vs. Benchtop RT-PCR
(n=119) positive negative
Positive 33 1 97% (85%,100%) PPV
negative 34 51 60% (49%,70%) NPV
49% (38%,61%) 98% (90%,100%)
Sensitivity Specificity
(95% CI).
doi:10.1371/journal.pone.0033176.t004
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specially designed to enable reactions over a wide range of Mg
2+
concentrations through a balanced combination of KCl and
(NH4)2SO4 [45]. The standard Qiagen assay was further
optimized by adding twice the amount of enzyme and more
BSA as a blocking agent to improve amplification in a high surface
to volume ratio environment (Figures S2, S3, S4). It has been
observed by others that enzyme can bind non-specifically to the
walls and become inactive in high surface to volume ratio reaction
chambers [46].
Key advantages of an integrated microfluidic chip are rapid
turnaround time, low cost, potential for portability (and thus true
point-of-care use) and reduced possibility of sample-to-sample
contamination. While much faster than most clinical laboratory
turn around times for molecular assays (which usually run more
than 4 hours), 3 hours is still too long for a true POC test. There
are several avenues available to improve the assay and reduce the
testing time. To meet the demands of a POC setting (e.g.
clinician’s office), the end-to-end time for the assay must be short
(less than one hour) and the hands-on time very short. The hands-
on time must include as few steps as possible, and the steps should
be easily performed by a minimally trained user. This end-to-end
time can be markedly reduced in our system through further
optimization. The loading and washing times could be reduced by
optimizing SPE compositions in the chip to allow for faster fluid
flow (larger pore sizes) and including multiple shorter columns in
parallel instead of one long column. These improvements are
expected shorten the loading and washing of the SPE to about
20 min. To reduce the PCR time, continuous flow PCR with real
time reading at each turn of the serpentine channel could further
reduce the cycling time by allowing the reader to see a positive
result before all 30 cycles of PCR were complete. With these two
modifications, the total turn-around-time could be reduced to less
than 1 hour making the assay suitable for true POC applications.
As in any proof of concept design, there are limitations in the
current embodiment. First, none of the reagents were stored on
chip and were added as required while running the assay.
Lyophilized reagents for RT and PCR are commercially available
and will be required for a self-contained system. Further, if
quantitative results are sought, the endpoint read is not a good
method, due to the saturation of PCR at high cycle numbers.
Quantitative results may not be useful in the case of influenza, but
are absolutely critical for other RNA virus diagnostic tests,
including those for HIV and HCV. Continuing efforts include
adding real time detection through the addition of fluorescence
imaging at several locations on the chip. Further, multiplex PCR
or spatial multiplexing, although not demonstrated on this device,
would greatly enhance the power of this technique and would be
imperative for an optimal influenza assay (i.e. the ability to detect
and distinguish influenza A and B).
Although this microfluidic chip shares some similarities with
other devices [47], it has several unique characteristics. This chip
is capable of analyzing clinical specimens directly with minimal
sample preparation. Here, we did spin down the initial sample
once before applying it to the microfluidic chip. This step was
performed to avoid clogging of the SPE columns by cell debris that
might be present in the sample, and it can be eliminated by using
SPE columns with larger average pore sizes as described above.
The chip has a single layer design and is made from a
thermoplastic material suitable for high throughput fabrication
using injection molding. Last, the fluidic and thermal controls are
very simple. Continuous-flow PCR eliminates the need to
thermocycle the entire chip. The flow is almost entirely regulated
by differential flow resistance between the functional chambers.
We demonstrated the feasibility of very simple control methods
using one pump, two heaters and 3 thermocouples. These items
would be packaged in a ‘‘reader’’ for an eventual stand-alone test.
In summary, a newly developed single use microfluidic assay
was demonstrated to amplify influenza A RNA in clinical
specimens with high sensitivity and specificity, with performance
essentially equivalent to standard bench-top RT-PCR. The
microfluidic assay is simple to fabricate and to run, since the
microfluidic device is a single layer with a cover, and the assay
steps follow in a linear progression without active valving on chip.
The sample introduction, static heating and pressure driven flow
have been automated with our collaborators for a very similar
bacterial detection assay [48] and these improvements could be
easily applied to the system demonstrated here. The parallel
development of a very simple, low cost reader with the form factor
of a clinical digital thermometer would meet the requirements for
bedside use. We see these results as a major step toward a true
POC molecular assay for influenza A, and this proof of concept
demonstration as a basis for the molecular detection and diagnosis
of a number of other infections.
Materials and Methods
Specimens and specimen characterization
A total of 626 NPA and NPS samples were collected during the
2008–2010 influenza seasons including the 2009 pandemic period.
The specimens were collected from adult and pediatric patients at
two hospitals in Boston, Massachusetts, USA; 383 from adult and
pediatric patients in the emergency room at Boston Medical
Center (BMC) and 243 from a combination of inpatients and
outpatients (almost all adults) from Beth Israel Deaconess Medical
Center (BIDMC). Each study was reviewed and approved by the
site’s institutional review board. The specimens collected at BMC
were collected prospectively and frozen; the specimens from
BIDMC were frozen discarded specimens that had been collected
and tested during routine clinical care. At BMC, informed consent
was obtained from all participants. All patients were consented in
writing and had the ability to withdraw from the study at any time.
Pediatric patients were consented in writing by their parent or
legal guardian in addition to being asked for verbal assent if they
were able. At both BMC and BIDMC, specimens were collected
from patients presenting with one or more symptoms consistent
with influenza, including fever, cough, sore throat, myalgia, nasal
congestion or rhinorrhea (runny nose), headache, malaise, or
diarrhea. Subjects had a distribution of ages ranging from 12
months to 70 years (as noted, specimens obtained from BIDMC
were almost exclusively from adults) and included both genders.
No subject was excluded based on race.
At BMC, NPA samples were taken from consented subjects
following standard techniques [49,50]. Briefly, the person
obtaining the sample measured the distance from the patient’s
nostril to the nasopharynx and held the tube at that location. A
0.6 mm619 mm6305 mm flexible sterile suction catheter was
placed through the nostril to the posterior nasopharynx. One to
2 ml of sterile saline was instilled through the catheter and the
aspirate was immediately collected with gentle suction while
simultaneously removing the catheter. The NPA was collected into
a sterile container of 1.5 ml of viral transport medium (VTM) (BD,
Franklin Lakes, NJ). Specimens were stored at BMC for no longer
than 72 hours at 4uC before deidentification, transfer and storage
at the Klapperich Laboratory. Specimens received at the
Klapperich Laboratory were immediately centrifuged at
5000 rpm for 5 min and stored as 0.5 ml aliquots at 280uC.
They were not spun again before testing. A subset of the samples
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care, by request of the treating physician. When a rapid test was
performed, the remainder of the sample was sent to the
Klapperich Laboratory for further testing.
Both NPA and NPS samples were taken at BIDMC, though the
vast majority of the specimens were swab (NPS) samples. In all
cases, specimens were taken from patients in the course of routine
clinical care, for testing ordered by the patient’s clinician. NPS
specimens were taken using two Copan flocked swabs (COPAN,
Murrieta, CA). The first swab was inserted flat and pushed
forward with gentle downward pressure on the lower nasal floor to
the posterior wall of the nasopharynx, where it was rotated for a
few seconds to collect cellular material. The swab was withdrawn
and placed into sterile 1X PBS. The collection procedure was
repeated using the second flocked swab in the other nostril; the
second swab was placed into M4RT (Remel, Lenexa, KS) media
for viral culture. The two swabs were then submitted on ice to the
BIDMC microbiology laboratory. After routine direct fluorescent
antigen (DFA, performed on the PBS tube in all cases [14]) and
culture (performed on the M4 tube in a subset of cases) testing,
tested/resulted specimens (approximately 1.0 mL) were stored at
280uC. In a minority of patients, NPA specimens were collected
instead of NPS specimens and submitted on ice to the BIDMC
clinical microbiology laboratory for testing, after which they were
frozen at 280uC. The frozen (discarded) NPS and NPA specimens
were later deidentified and sent to the Klapperich Laboratory
where they continued to be stored at 280uC. Before testing, all
specimens were routinely quick thawed from 280uCi na3 7 uC
water bath. Then the specimens were spun at 13,000 rpm for
10 min at 4uC to remove human cell debris and mucous, and the
supernatant was used for all downstream testing.
Microfluidic Chip Fabrication
The microfluidic chips were fabricated in thermoplastic Zeonex
690R (Zeon Chemicals, Louisville, KY), by hot-embossing a blank
0.7 mm thick Zeonex plaque using an epoxy master mold and
then thermally sealing the imprinted channel with a 0.7 mm blank
Zeonex cover slip [51]. Three open ports in the chip were fitted
with nanoports (Upchurch Scientific, Oak Harbor, WA) using
epoxy glue to facilitate loading the specimen, adding the reagents
and collecting the RT-PCR products. The entire chip is 70 mm in
length, 25 mm in width and 1.4 mm in height. The integrated
chip consists of three functional chambers, a solid phase extraction
(SPE) column for RNA extraction, an RT chamber, and the PCR
channel. The sample preparation channel was fabricated following
methods described in earlier work [52,53]. All reagents for SPE
column fabrication were purchased from Sigma (St. Louis, MO)
unless otherwise noted. Before fabrication of the SPE column, the
channel was cleaned with 50 ml RNAse Away, (Molecular
BioProducts, San Diego, CA), and then rinsed with 100 ml
nuclease free water (Promega, Madison, WI). Briefly, silica
microspheres (0.7 mm, cat# 24324-15, Polysciences Inc.) were
prepared by centrifugation for 5 min at 6600 rpm, aspirating the
suspension solution, and drying on a heat block overnight to
remove excess water. The inner channel surface was grafted with
97% v/v methyl methacrylate and 3% v/v benzophenone by
10 min of UV-irradiation at 265 nm in an Ultraviolet Crosslinker
(CL-1000, UPV Inc., Upland, CA). This step facilitated covalent
attachment between the SPE column and the inert plastic channel
surface. The SPE column itself was made with a mixture of 16%
v/v ethylene dimethacrylate, 24% butyl methacrylate, 42% 1-
dodecanol, 18% cyclohexanol, and 1% photoinitiator 2-dimethy-
lamino-4-(methyl-phenylamino)-phenol. Silica microspheres were
added into the monolith solution in a 1:1 ratio (v/v). The monolith
was then cross-linked by UV irradiation for 5 min as above
through both sides of the chip, achieved by flipping the chip over
half way through irradiation. Before use, chips were cleaned with
500 mL of 100% methanol to rinse away excess porogen and to
create the open pore structure of the SPE.
The Microfluidic Assay
The first chamber of the chip is an SPE column for sample
preparation; it is integrated directly with the RT and PCR steps.
Sample preparation followed the same strategy as previously
reported [54]. Briefly, before introducing the sample, the channel
was conditioned with 300 mL of buffer containing 1.5 M
guanidine thiocyanate (GuSCN) (Sigma, St. Louis, MO), 50% 2-
Propanol (Sigma), and 1X RNASecure (Applied Biosystems,
Foster City, CA). Next, 100 ml of the NPA or NPS specimen
was mixed with 300 ml lysis buffer (2 M GuSCN, 66.7% 2-
propanol, 1x RNASecure, 6 mg carrier RNA (Qiagen, Valencia,
CA)). This mixture was run though the channel and collected from
the first outlet port. During this step, nucleic acids released from
the lysed influenza particles in the specimen bind to the SPE
column. The SPE channel was then cleaned sequentially with
50 ml of 70% ethanol followed by 50 ml of 100% ethanol, which
were also collected at the first outlet (to waste). The residual
ethanol was removed by passing 500 mL of dry air through the
channel. Finally, the extracted RNA was eluted in 13–15 mlo f
nuclease free water. The flow rates for all steps were between 0.8–
1 ml/hr. All fluids were pushed using a programmable syringe
pump (PHD2000, Harvard Apparatus, MA).
The extracted RNA was amplified by RT-PCR on-chip using
reagents from the One Step RT-PCR kit (Qiagen). The CDC
influenza A primers were used (see below), targeting the highly
conserved M1 gene and generating a 106 bp amplicon [39]. Each
50 ml RT-PCR reaction included 13.5 ml RNA, 4 ml one step RT-
PCR enzyme mix, and the following reagents with the given final
concentrations: 1X Q solution, 1X one step buffer, 1 mM
additional MgCl2, 1 mM forward primer 59-GAC CRA TCC
TGT CAC CTC TGA C-39, 1 mM reverse primer 59-AGG GCA
TTY TGG ACA AAK CGT CTA-39, 400 mM dNTP, 0.015%
w/v BSA, and 0.75% w/v PEG8000. The PCR products were
analyzed using a 2100 Bioanalyzer and sequenced using the PCR
primers. Influenza A/PR/8/34 cultured in Madin-Darby canine
kidney (MDCK) cells was used as the chip positive control and
nuclease free water was the chip negative control.
After the extracted RNA was eluted and collected in the well at
the end of the SPE channel, the RT-PCR reagents were loaded,
and the solution was pushed into the RT chamber. The RT
chamber was maintained at 50uC for 30 min, followed by 95uC
for 15 min to activate the PCR enzyme according to the
manufacturer’s protocol. Next the reaction flowed through the
continuous-flow PCR channel for amplification. A denaturation
temperature of 95uC and annealing temperature at 60uC were
applied through the thin film heaters. The flow rate was 0.6 ml/
min, resulting in a 40 sec cycle time. The reaction products were
collected in the second outlet port 30 cycles (20 min).
Bench Top Quantitative PCR
For the off-chip control reactions, RNA was extracted from
140 ml of each specimen using the QIAamp Viral RNA Mini Kit
(Qiagen) as per the manufacturer’s protocol. First strand cDNA
synthesis (RT) and amplification (PCR) steps were combined by
using the SuperScript III PlatinumH One-Step qRT-PCR Kit w/
ROX (Invitrogen, Carlsbad, CA). The pan A Universal primers
and probes used were (Biosearch Technologies, Novato, CA)
influenza A forward primer: 59 GAC CRA TCC TGT CAC CTC
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CGT CTA 39, and probe: 59 TGC AGT CCT CGC TCA CTG
GGC ACG 39. For influenza B, the primers were forward primer:
59 TCC TCA AYT CAC TCT TCG AGC G 39, reverse primer:
59 CGG TGC TCT TGA CCA AAT TGG 39, and probe: 59
CCA ATT CGA GCA GCT GAA ACT GCG GTG 39 [39]. All
reactions were performed in a 7300 Real Time PCR system
(Applied Biosystems, Foster City, CA) under the following
conditions: 30 min at 50uC for RT, 15 min at 95uC for
polymerase activation, followed by 45 cycles of 15 sec at 95uC
and 60 s at 55uC for amplification. The primers, reagents and
amplification scheme are as described in the CDC protocol for
real time RT-PCR for influenza A and B (H1N1) [39].
A standard curve was established for each qRT-PCR using
plasmids containing a single copy of the influenza A M1 sequence
targeted by the PCR primers (SeqWright, Houston, TX). The
plasmid was generated by cloning the M1 PCR product with the
pCR 2.1 TOPO-TA cloning kit (Invitrogen) and quantified with
PicoGreen to prepare plasmid dilutions of 10
7 to 10
1copies/ml.
The viral cDNA copy number generated from a given patient
specimen was determined by interpolation from a standard curve
of cycle threshold (CT) values based on the known input
concentrations of plasmid DNA.
Microfluidic chip product validation
Results available from the clinical laboratories at each site
varied (DFA results were available for all specimens from
BIDMC, and rapid assay results were available for a subset of
cases from BMC specimens). In order to establish a ‘‘gold
standard’’ method across all of the samples, we re-tested all of the
samples using standard bench top quantitative RT-PCR for both
influenza A and influenza B. The results of this quantitative PCR
were used to calculate the statistical performance of the
microfluidic assay.
For the microfluidic assays, positive and negative specimens
were tested in a random order, and each specimen was tested on a
new chip to avoid cross contamination. The 146 samples selected
for testing with the microfluidic assay were not chosen with regard
to viral load or any other parameter. Previously unthawed aliquots
were preferentially used to reduce potential viral degradation in
the sample. The concentration and product size of microfluidic
assay PCR products from all specimens was analyzed by gel
capillary electrophoresis on a 2100 Bioanalyzer (Agilent, Santa
Clara, CA) with the High Sensitivity DNA Kit (Agilent). The
correct product size was also confirmed for all positive samples by
12% PAGE. Every 10
th negative sample from each week was
verified as negative by 12% PAGE.
Every 10
th positive sample was sequenced (SeqWright, Houston,
TX or Genewiz, South Plainfield, NJ) to verify the product
sequence as the correct fragment of the M1 gene of influenza A.
The PCR products (10 ml) were cleaned up with ExoSAP-ItH
(USB Scientific, CA) and then sequenced using PCR primers.
Sequences from the chip amplicons were analyzed by standard
methods. Briefly, all GenBank influenza type A M1 gene
sequences from 2008–2010, from humans in North America
(n=739) were retrieved from the Influenza Virus Resource
database at the National Center for Biotechnology Information
(NCBI) [40]. The sequences were aligned using ClustalX [55]
using the M1 sequence of influenza A/PR/8/34 (accession
number NC_002016) as the reference.
Statistical Analysis
A total of 73 influenza A positive patient specimens and 73
influenza A negative patient specimens were selected from the
banked samples and were tested using the microfluidic assay. We
targeted demonstration of 95% sensitivity. In order to have the
statistical power to demonstrate sensitivity 95% or better, with a
prevalence of 50% (input sample pool was adjusted) with a
confidence interval of 0.05, a sample size of 146 was required.
The 73 negative samples included some samples that were
negative for influenza A, but positive for influenza B by the
bench top RT-PCR assay. The sensitivity, specificity, positive
predictive value (PPV), and negative predictive value (NPV) were
determined using standard methods [56] and are reported as
comparisons to standard bench top qRT-PCR, which is
emerging as the gold standard test method [42,57]. One-way
ANOVA (95% CI) was performed to determine the significance
of relationships between viral load and sample type (NPA or
NPS) on the microfluidic assay PCR product yield. Microsoft
Excel and GraphPad Prism (v5, La Jolla, CA) were used for the
analyses.
Rapid immunoassays and DFA
The Xpect
TM Flu A & B kit (Remel, Lenexa, KS) and the
BinaxNOW
TM Influenza A & B kit (Inverness Medical, Princeton,
NJ) were used as per the manufacturer’s protocols at the BMC
emergency departments. These tests were ordered at the discretion
of the attending clinician. The rapid immunoassay tests were
performed using a small amount of the same NPA collected for
this study. DFA assays were conducted at BIDMC as previously
described [14].
Supporting Information
Figure S1 Microfluidic assay performance using cul-
tured influenza A virus and standard Qiagen OneStep
Kit protocol.
(TIF)
Figure S2 Microfluidic assay performance using cul-
tured influenza A as a function of increasing BSA
concentrations. The baseline assay contains no additional BSA.
(TIF)
Figure S3 Microfluidic assay performance as a function
of increasing MgCl2 concentration. The baseline assay has
2.5 mM of MgCl2.
(TIF)
Figure S4 Microfluidic assay performance as a function
of increasing enzyme concentration. The baseline assay
contains 2 ml of the enzyme master mix. The manufacturer does
not give the concentration in IU.
(TIF)
Table S1 Summary of the patient specimens tested in
the microfluidic assay and bench top RT-PCR.
(XLS)
Table S2 Summary of the patient specimens tested by
DFA and bench top RT-PCR.
(XLS)
Table S3 Summary of the patient specimens tested by
rapid immunoassay and bench top RT-PCR.
(XLS)
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